Literature DB >> 12102159

Clustering of individuals with both breast and ovarian cancer--a possible indicator of BRCA founder mutations.

Zakaria Einbeigi1, Jeanne M Meis-Kindblom, Lars-Gunnar Kindblom, Arne Wallgren, Per Karlsson.   

Abstract

In a cohort of 60436 women with a diagnosis of invasive breast carcinoma and known to reside in Sweden in 1960, 321 had a subsequent diagnosis of ovarian carcinoma. Assuming no correlation between the two cancers, one would expect that 191 women would develop ovarian cancer (standardized incidence ratio (SIR) 1.7; 95% confidence interval 1.5-1.9). Women with breast cancer before 40 years of age were at highest risk for developing ovarian cancer (SIR 4.5). Between 40 and 49 years of age, the SIR was 1.9, and at 50 years of age or older, the SIR was 1.3. Most of the excess in ovarian cancer occurred in southern Sweden. The geographic distribution of these cases coincided with the distribution of families with known BRCA1 and BRCA2 gene mutations. These results suggest that genetic factors account for the excess in ovarian cancer that occurs in breast cancer patients and that geographic clustering of patients who have both breast and ovarian cancer may indicate the presence of a BRCA founder mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102159     DOI: 10.1080/028418602753669526

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

2.  Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

Authors:  Oubaida ElBiad; Abdelilah Laraqui; Fatima El Boukhrissi; Chaimaa Mounjid; Maryame Lamsisi; Tahar Bajjou; Hicham Elannaz; Amine Idriss Lahlou; Jaouad Kouach; Khadija Benchekroune; Mohammed Oukabli; Hafsa Chahdi; Moulay Mustapha Ennaji; Rachid Tanz; Yassir Sbitti; Mohammed Ichou; Khalid Ennibi; Bouabid Badaoui; Yassine Sekhsokh
Journal:  BMC Cancer       Date:  2022-02-25       Impact factor: 4.430

3.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.